Salmeterol and fluticasone propionate given as a combination - Lack of systemic pharmacodynamic and pharmacokinetic interactions

European Journal of Clinical Pharmacology

Volumn 56, Issue 11, 2001, Pages 781-791

  Kirby, S ^a   Falcoz, C ^a   Daniel, M J ^a   Milleri, S ^b   Squassante, L ^b   Ziviani, L ^b   Ventresca, G P ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANE DERIVATIVE; BETA ADRENERGIC RECEPTOR; BRONCHODILATING AGENT; CORTICOSTEROID; FLUTICASONE; SALBUTAMOL; SALMETEROL;

ADULT; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; DRUG INTERACTION; FEMALE; GENETICS; HALF LIFE TIME; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; ALBUTEROL; ANALYSIS OF VARIANCE; ANDROSTADIENES; AREA UNDER CURVE; BLOOD PRESSURE; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, ADRENERGIC, BETA;

EID: 0034465395     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280000233     Document Type: Article

References (39)

1. Gerritsen J, Koeter GH, Postma DS, Schouten JP, Knol K (1989) Prognosis of asthma from childhood to adulthood. Am Rev Respir Dis 140: 1325-1330
2. Barnes PJ (1989) A new approach to the treatment of asthma. N Engl J Med 321: 1517-1527
3. British Thoracic Society (1997) The British guidelines on asthma management. Thorax 52[Suppl 1]: S1-S21
4. Holliday SM, Faulds D, Sorkin EM (1994) Inhaled fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma. Drugs 47: 318-331
5. Fabbri L, Burge PS, Croonenborgh L, Warlies F, Wecke B, Ciaccia A, Parker C (1993) Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. Thorax 48: 817-823
6. Chervinsky P, Van As A, Bronsky EA (1994) Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. J Allergy Clin Immunol 94: 676-683
7. Mackie AE, Ventresca GP, Fuller RW, Bye A (1996) Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. Br J Clin Pharmacol 41: 539-542
8. Falcoz C, Mackie AE, McDowall J, McRae J, Yogendran L, Ventresca GP, Bye A (1996) Oral bioavailability of fluticasone propioante in healthy subjects. Br J Clin Pharmacol 41: 459P-460P
9. Brogden RN, Faulds D (1991) Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 42: 895-912
10. Pearlman DS, Chervinsky P, LaForce C, Seltzer JM, Southern DL, Kemp JP, Dockhorn RJ, Grossman J, Liddle RF, Yancey SW, Cocchetto DM, Alexander WJ, Van As A (1992) A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med 327: 1420-1425
11. Greening AP, Ind PW, Northfield M, Shaw G (1994) Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing corticosteroid. Lancet 344: 219-224
12. Woolcock A, Lundback B, Ringdal N, Jacques LA (1996) Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 154: 1481-1488
13. Ind PW, Dal Negro R, Colman NC, Fletcher CP, Browning DC, James MH (1998) Inhaled fluticasone propionate and salmeterol in moderate adult asthma I: Lung function and symptoms. Am J Respir Crit Care Med 157: A416
14. Ind PW, Dal Negro R, Colman NC. Fletcher CP, Browning DC, James MH (1998) Inhaled fluticasone propionate and salmeterol in moderate adult asthma II: Exacerbations. Am J Respir Crit Care Med 157: A415
15. Manchee GR, Eddershaw PJ, Ranshaw LE, Herriott D, Park GR, Bayliss MK, Tarbit MH (1996) The aliphatic oxidation of salmeterol to α-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A. Drug Metab Dispos 24: 555-559
16. Falcoz C, Lawlor C, Hefting NR, Borgstein NG, Smeets FWM, Wemer J, Jonkman JHG, House F (1997) Effects of CYP450 3A inhibition by ketoconazole on systemic activity of inhaled fluticasone propionate and budesonide. Eur Respir J 10[Suppl 25]: 175S-176S
17. Conolly ME, Hui Kit Ka, Borts SE, Jenne JW (1987) Beta-adrenergic tachyphylaxis (desensitization). In: Jenne JW, Murphy S (eds) Drug therapy for asthma. Marcel Dekker, New York, pp 259-290
18. Mackie AE, Falcoz C, McDowall JE, Moss J, Ventresca GP, Bye A (1997) Pharmacokinetics of fluticasone propionate inhaled from the Diskhaler and the Diskus powder devices in healthy subjects. Br J Clin Pharmacol 43: 540P-541P
19. 2-adrenergic receptor and asthma. Am J Respir Crit Care Med 156: S156-S162
20. 2-adrenergic receptor expression: correlation between receptor density, function and genotypes. Thorax 51: A38
21. 2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet 345: 1213-1214
22. Jones AE, Callejas S, Sadra P, Joyce K, Pereira A, Biddlecombe RA. Pleasance S (1997) The determination of drugs for the treatment of asthma in plasma by automated solid phase extraction and EC-MS-MS. In: Proceedings of the 45th ASMS conference on mass spectrometry and allied topics. Palm Springs. Jun 1-5, 1997, p 560
23. Callejas SL, Biddlecombe RA, Jones AE, Joyce KB, Pereira AI, Pleasance S (1998) Determination of the glucocorticoid fluticasone propionate in plasma by automated solid phase extraction. J Chromatogr B 718: 243-250
24. Hollander X, Wolfe DA (1973) Non-parametric statistical methods. Wiley, New York, pp 26-66
25. Maconochie JG, Minton NA, Chilton JE, Keene ON (1994) Does tachyphylaxis occur to the non-pulmonary effects of salmeterol? Br J Clin Pharmacol 37: 199-204
26. Man CY, Palmer HE, Squassante LS, Ventresca GP (1994) Tachyphylaxis to the metabolic systemic effects of inhaled salmeterol in healthy subjects. Eur Respir J 7[Suppl 18]: P572
27. 2-adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients. Thorax 50: 497-504
28. Casty FE, Stahl E, Wisniewski M, Alexander WJ and the Salmeterol MDI Study Group (1995) Holter monitoring results in patients using salmeterol or albuterol with and without inhaled corticosteroids. Am J Respir Crit Care Med 151: A269
29. Man CY, Kirby SM, McRae J, Ventresca GP (1996) Systemic pharmacodynamic effects of salmeterol in the salmeterol/FP combination DiskusTM inhaler. Eur Respir J 9[Suppl 23]: 164S
30. 2-adrenoceptor function in asthmatic patients. Chest 109: 343-347
31. 2-adrenoceptor function in asthmatic subjects. Br J Clin Pharmacol 44: 505-508
32. 2-adrenoceptor subsensitivity induced by formoterol. Br J Clin Pharmacol 42: 654P-655P
33. Tan KS, Grove A, MacLean A, Gnosspelius Y, Lipworth BJ (1997) Systemic corticosteroid rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. Am J Respir Crit Care Med 156: 28-35
34. Falcoz C, Mackie AE, Horton J, Brown A, Field E, Harding SM, Wire P (1997) Pharmacokinetics of fluticasone propionate inhaled from the Diskhaler and the Diskus powder devices in asthmatic patients. Br J Clin Pharmacol 43: 541P-542P
35. 2-agonist therapy. Eur J Clin Pharmacol 54: 377-381
36. Hindle M, Chrystyn H (1992) Determination of the relative bioavailability of salbutamol to the lung following inhalation. Br J Clin Pharmacol 34: 311-315
37. Bennett JA, Tattersfield AE (1997) Time course and relative dose potency of systemic effects from salmeterol and salbutamol in healthy subjects. Thorax 52: 458-464
38. Ward JK, Man CY, Horton J, Ventresca GP (1997) Systemic dynamic responses to oral doses of salmeterol in healthy subjects - effect of activated charcoal. Am J Respir Crit Care Med 155: A346
39. Rohatagi S, Bye A, Falcoz C, Mackie AE, Meibohm B, Mollman H, Derendorf H (1996) Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. J Clin Pharmacol 36: 938-941